Novo Nordisk's Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it works
Novo Nordisk
has officially launched
Wegovy
, its much-talked-about weight loss injection. The company is now competing directly with Eli Lilly's popular drug,
Mounjaro
.
Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn't require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India reported.
India's obesity market is growing fast
India has one of the world's highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the
anti-obesity medicine
market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge opportunity.
Shrotriya said, 'Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.'
Live Events
How Wegovy Works
Wegovy contains a compound called
semaglutide
, which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight loss.
It comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food cravings.
According to Dr V. Mohan, a well-known diabetologist, 'Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It's a strong option for Indian patients dealing with both obesity and rising heart risks.'
Wegovy India Price List
Dose
Monthly Price (Rs)
Price Per Dose (Rs)
0.25 mg
Rs 17,345
Rs 4,366
0.5 mg
Rs 17,345
Rs 4,366
1 mg
Rs 17,345
Rs 4,366
1.75 mg
Rs 24,280
Rs 6,070
2.4 mg
Rs 26,015
Rs 6,503
For comparison, Eli Lilly's Mounjaro is slightly cheaper:
Mounjaro Dose
Monthly Price (Rs)
2.5 mg
Rs 14,000
5 mg
Rs 17,500
Almost like weight loss surgery, but with a catch
Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver health.
However, the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly monitored.
Wegovy vs Mounjaro: What's the Difference?
Feature
Wegovy (Semaglutide)
Mounjaro (Tirzepatide)
How it works
Mimics GLP-1 hormone
Acts on GLP-1 and GIP hormones
Effect
Lowers appetite, slows digestion
Improves insulin and reduces appetite
Approved for
Weight loss
Diabetes (off-label for weight loss)
How to use
Weekly injection via Flexpen
Weekly injection via vial
Price range
Rs 17,345–Rs 26,015
Rs 14,000–Rs 17,500
Inputs from TOI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
21 minutes ago
- Indian Express
323 PGI staff houses lie vacant, causing Rs 5.5 crore annual loss
As many as 323 houses meant for faculty and non-faculty staff of the Post Graduate Institute of Medical Education and Research (PGI) in Sectors 12 and 24 have been lying vacant for years, causing an annual financial loss of around Rs 5.5 crore, information obtained under the Right to Information (RTI) Act has revealed. According to the RTI reply, the losses are on account of forgone licence fees and the payment of 20% house rent allowance (HRA) to staff who could have been accommodated in these quarters. Over the last five to six years, the non-allotment of vacant houses has cost PGI more than Rs 20 crore. Applicant Ashwani Kumar Munjal, an honorary member of the PGI Employees' Union (Non-Faculty), said many of these houses have remained unoccupied from 2017 to 2025, even as several employees wait for official accommodation. 'Staff have to rent homes in far-off areas at high rates. This puts a heavy financial burden on them and delays their arrival for duty due to traffic congestion, ultimately affecting patient services,' he said. The RTI reply also shows that many of these houses have been locked up for years, rendering them uninhabitable. While PGI suffers rental losses running into several lakh rupees annually, it continues to incur expenses on the upkeep and security of these properties. Residential accommodation at PGI is primarily meant for faculty, resident doctors, nurses, and other staff. However, due to various reasons — from long-pending repairs to unsuitable location or size — 323 houses remain unallotted. A recent 'fitness report' of the vacant quarters flagged severe issues, including wall cracks, leaking roofs, faulty sewage and plumbing systems, unsafe electrical wiring, and dilapidated doors and windows. These problems have delayed allotment and driven up annual maintenance costs. Meanwhile, demand for on-campus housing remains high, with new doctors and employees often forced to rent costly accommodation outside. Staff representatives say timely repair and maintenance could prevent further financial losses and ease the housing crunch. Proposals under consideration include earmarking a separate repair budget and launching large-scale renovations to bring the locked quarters back into use.
India Today
an hour ago
- India Today
Indian-origin US doctor fined $2M for false surgery billing fraud
A 63-year-old Indian-origin pain medicine doctor based in Houston, Texas, has agreed to pay more than $2 million (approximately Rs 17.4 crore) to settle allegations of healthcare fraud, according to the US Ajay Aggarwal agreed to pay $2,053,515 to resolve claims that he submitted false billing to Medicare and to the Department of Labor's Workers' Compensation Programs between November 2021 and March 2023, for surgical procedures that were never actually is an anesthesiologist and pain medicine doctor who also practices in Texas' Bellaire city, Lake Jackson city and Van Vleck (in Matagorda County). He runs his medical practice, called The Pain Relief & Wellness Center, through his own business and a company named PRWCSWTX LLC, according to the statement issued on Monday (August 11) by the US Attorney's Office, Southern District of Texas. Aggarwal billed federally funded healthcare programmes for the surgical implantation of neurostimulator electrodes, according to the statement. These are invasive procedures usually requiring use of an operating room. As a result, Medicare and other federally funded healthcare programmes pay thousands of dollars per procedure, the statement neither Aggarwal nor his staff performed these surgical procedures, according to the allegations, the statement further investigators said Aggarwal instead used electro-acupuncture devices on his patients, which involved inserting thin wires into the ear and taping a small neurostimulator behind the ear – none of which required surgery or treatments were done at Aggarwal's clinic, not a hospital or surgical centre, and no incision was made on a patient, according to the VOWS TO RECOVER LOSSES FROM FRAUDULENT MEDICARE BILLINGUS attorney Nicholas J Ganjei slammed the "fraudulent billing" by the doctor and vowed to recover the losses."A doctor who uses simple medical devices on his patients, yet bills Medicare for a sophisticated spinal surgery, is bilking the American taxpayer, plain and simple," said Ganjei."The Southern District of Texas will ensure that losses to federally funded healthcare programs from fraudulent billing, like what happened here, are recouped and that wrongdoers are held accountable," the attorney month, a doctor of Indian-origin admitted guilt to federal charges related to illegally prescribing strong opioids, resulting in the overdose deaths of two part of his plea, Sanjay Mehta admitted to writing unjustified prescriptions for oxycodone, methadone, and Roxicodone (a branded form of oxycodone hydrochloride) to three different patients in Virginia."Two of the three customers died of opioid intoxication within days of receiving their unlawful prescriptions," US Attorney's Office said in a quantum of Mehta's punishment will be announced on October 31.- Ends
Mint
2 hours ago
- Mint
Stakeholder consultation by FSSAI charts roadmap for transparent, responsible food labelling in India
New Delhi [India], August 13 (ANI): The Food Safety and Standards Authority of India (FSSAI) convened a high-level National Stakeholder Consultation on Food Labelling, Advertisement and Claims here in the national capital, bringing together over 700 participants from government, industry, academia, consumer bodies, and regulatory authorities. According to a statement from the Ministry of Health and Family Welfare, the consultation aimed to review existing regulations, address implementation challenges, and align India's standards with global best practices to boost consumer protection, public health, and industry innovation. In her inaugural address, Health Secretary Punya Salila Srivastava stressed the importance of ethical and truthful practices in the rapidly evolving food sector. "We are now exposed to the entire world, which means we must adopt positive changes and scrutinise food products more closely," she noted, adding that such consultations are "vital" in shaping future policy. Nidhi Khare, Secretary, Department of Consumer Affairs, called for an end to misleading advertising and urged manufacturers to treat labelling as a "factor of trust" rather than merely a marketing tool. "Consumers should be left to make the final choice based on truthful and honest declarations," she emphasised, urging collective responsibility to ensure accuracy and transparency in product information. Sanjeev Sanyal, Member, Economic Advisory Council to the Prime Minister, underscored the need for external validation of scientific claims in advertisements. He welcomed FSSAI's decision to implement all label changes annually on July 1, reducing uncertainty for the labelling industry. Additional Secretary, Ministry of Information and Broadcasting, Prabhat, warned against false health and nutrition claims, highlighting their potential to erode public trust and harm health. The event featured technical sessions on global and Indian regulatory frameworks, enforcement case studies, and interactive discussions. Stakeholders exchanged insights on industry accountability, consumer rights, and collaborative enforcement strategies, resulting in actionable recommendations to enhance transparency and trust in food labelling and advertising. This consultation is part of FSSAI's ongoing national dialogue series aimed at building practical, health-aligned policies through close collaboration with industry, academia, and consumer organizations. (ANI)
